Evidence map›Paper›PMID 41375127›Full record

ReviewMolecules (Basel, Switzerland)2025

Development of Prediction Capabilities for High-Throughput Screening of Physiochemical Properties by Biomimetic Chromatography.

Damian Tuz, Damian Smuga, Tomasz Pawiński

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Damian TuzLaboratory of Physicochemical Analysis, Department of Medicinal Chemistry, Celon Pharma S.A., Marymoncka 15, 05-152 Kazuń Nowy, Poland.ORCID 0009-0001-8621-7571
Damian SmugaLaboratory of Physicochemical Analysis, Department of Medicinal Chemistry, Celon Pharma S.A., Marymoncka 15, 05-152 Kazuń Nowy, Poland.ORCID 0000-0001-6270-0238
Tomasz PawińskiDepartment of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.ORCID 0000-0001-9110-4312

Funding

Polish Ministry of Science and Higher Education DWD/8/0390/2024
6 · The paper itself

Abstract

The ever-increasing costs of in vitro and in vivo testing are compelling scientists to increasingly rely on computational models for predictive characterisation at early stages of drug discovery and development. The complexity of this stage requires high-throughput screening methods that can rapidly generate comprehensive information about new chemical compounds. This review explores innovative approaches assessing pharmacokinetic and pharmacodynamic properties of new chemical entities, with a focus on integrating machine learning as a transformative analytical tool. Machine learning algorithms are highlighted for their capability to train sufficient predictors combining biomimetic chromatography data (a high-throughput alternative for several physicochemical assays) with molecular features and/or molecular fingerprints obtained in silico and in vivo data of known compounds to allow efficient prediction of in vivo data for new chemical entities. By synthesising recent methodological advancements and giving useful practical approaches, the review provides insights into computational strategies that can significantly accelerate compound library screening and drug development processes.

Indexed as

BiomimeticsChromatographyDrug DiscoveryHigh-Throughput Screening AssaysMachine LearningHumansPharmacokineticsQuantitative Structure-Activity Relationshipbiomimetic chromatographyhigh-throughputmachine learningscreening

Identifiers

PMID41375127
PMCPMC12693484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.